The LRG Impacts GIST Research
Thriving Together also means impacting GIST research for our patient community. The LRG contributes and collaborates in the research arena in many ways.
New Life Raft Group Paper Published
The LRG publishes, "Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry" Cancer Investigation ,Vol. 41, 2023. Issue 5 [...]
Our Latest Publication Focused on Mutational Testing
The LRG published "Barriers to mutational testing in patients with gastrointestinal stromal tumors (GIST) – a survey of Life Raft Group members" in BMC Gastroenterology, November 2022.
Collaborative Effort Produces Position Paper on Need for Advanced Biomarker Testing
The Life Raft Group was recently part of team of authors on a collaborative position paper entitled 'Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type published' in Pathology: The Journal of the Royal College of Pathologists of Australia.
Breaking News: Additional Commentary for “It’s Time to Rethink Placebos in Advanced GIST” – LRG Science
In this issue of LRG Science, we present additional commentary on our Sept. issue: "It's Time to Rethink Placebos in Advanced GIST".
It’s Time to Rethink Placebos in Advanced GIST – LRG Science
In this issue of LRG Science: based on current studies, this article asserts the belief that placebos do not benefit patients with advanced disease.
Life Raft Group Participates in Virtual CTOS Conference
The annual meeting of CTOS (Connective Tissue Oncology Society) will be held virtually this year due to the global pandemic.
Conversations with the LRG: Staying Alive in Difficult Times
In this presentation, Executive Director, Norman Scherzer will be joined by staff member and Data Analyst, Jerry Call and by Professor David Josephy to discuss relevant scientific topics including the impact of COVID-19 on GIST patients, and thoughts on promising research for GIST.
Survival in Advanced GIST Has Improved Over Time – LRG Science
In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.
Increasing the Quality and Efficiency of Clinical Trials
The mission of the Clinical Trials Transformation Initiative (CTTI) is to develop and drive the adoption of practices that will increase the quality and efficiency of clinical trials.